

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10589866
Filing Date	2006-09-19
First Named Inventor	BERCOVIER
Art Unit	1645
Examiner Name	DEVI
Attorney Docket Number	27637U

<b>U.S.PATENTS</b>						<b>Remove</b>		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.						<b>Add</b>		
<b>U.S.PATENT APPLICATION PUBLICATIONS</b>						<b>Remove</b>		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.						<b>Add</b>		
<b>FOREIGN PATENT DOCUMENTS</b>						<b>Remove</b>		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button						<b>Add</b>		
<b>NON-PATENT LITERATURE DOCUMENTS</b>						<b>Remove</b>		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T <sup>5</sup>	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <b>( Not for submission under 37 CFR 1.99)</b>		Application Number	10589866
		Filing Date	2006-09-19
		First Named Inventor	BERCOVIER
		Art Unit	1645
		Examiner Name	DEVI
		Attorney Docket Number	27637U

	1	NIGOU, et al., "Mannosylated Lipoarabinomannans Inhibit IL-12 Production by Human Dendritic Cells: Evidence for a Negative Signal Delivered Through the Mannose Receptor", The Journal of Immunology, vol. 166, pgs. 7477-7485, (2001).	<input type="checkbox"/>
	2	NIGOU, et al., "Mycobacterial lipoarabinomannans: modulators of dendritic cell function and the apoptotic response", Microbes and Infection, vol. 4, pgs. 945-953, (2002).	<input type="checkbox"/>
	3	OLSON, et al., "Design and Synthesis of a Protein β-Turn Mimetic", J. Am. Chem. Soc., vol. 112, pgs. 323-333, (1990).	<input type="checkbox"/>
	4	PINCUS, et al., "Peptides That Mimic the Group B Streptococcal Type III Capsular Polysaccharide Antigen", The Journal of Immunology, vol. 160, pgs. 293-298, (1998).	<input type="checkbox"/>
	5	PRINZIS, et al., "Structure and antigenicity of lipoarabinomannan from Mycobacterium bovis BCG", Journal of General Microbiology, vol. 139, pgs. 2649-2658, (1993).	<input type="checkbox"/>
	6	QUESNIAUX, et al., "Toll-Like Receptor 2 (TLR2)-Dependent-Positive and TLR2-Independent-Negative Regulation of Proinflammatory Cytokines by Mycobacterial Lipomannans", The Journal of Immunology, vol. 172, pgs. 4425-4434, (2004).	<input type="checkbox"/>
	7	SCHLESINGER, et al., "Binding of the Terminal Mannosyl Units of Lipoarabinomannan from a Virulent Strain of Mycobacterium Tuberculosis to Human Macrophages", Journal of Immunology, vol. 152, pgs. 4070-4079, (1994).	<input type="checkbox"/>
	8	SETHI, et al., "Contraction-Mediated Pinocytosis of RGD-Peptide By Dermal Fibroblasts: Inhibition of Matrix Attachment Blocks Contraction and Disrupts Microfilament Organisation", Cell Motility and Cytoskeleton, vol. 52, pgs. 231-241, (2002).	<input type="checkbox"/>
	9	SHIRAKAWA, et al., "The Inverse Association Between Tuberculin Responses and Atopic Disorder", Science, vol. 275, pgs. 77-79, (1997).	<input type="checkbox"/>
	10	SHIRTCLIFFE, et al., "An inverse correlation between estimated tuberculosis notification rates and asthma symptoms", Respirology, vol. 7, pgs. 153-155, (2002).	<input type="checkbox"/>
	11	SINGH, et al., "Advances in Vaccine Adjuvants for Infectious Diseases", Current HIV Research, vol. 1, pgs. 309-320, (2003).	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <b>( Not for submission under 37 CFR 1.99)</b>		Application Number	10589866
		Filing Date	2006-09-19
		First Named Inventor	BERCOVIER
		Art Unit	1645
		Examiner Name	DEVI
		Attorney Docket Number	27637U

	12	SMITH, et al., "Libraries of Peptides and Proteins Displayed on Filamentous Phage", Methods in Enzymology, vol. 217, pgs. 228-257, (1993). <input type="checkbox"/>
	13	STERN, et al., "Helical epitopes determined by low-stringency antibody screening of a combinatorial peptide library", FASEB J., vol. 11, pgs. 147-153, (1997). <input type="checkbox"/>
	14	TEMKIN, et al., "Tumor necrosis factors in a murine model of allergic peritonitis: effects on eosinophil accumulation and inflammatory mediators' release", Cytokine, vol. 24, pgs. 74-80, (2003). <input type="checkbox"/>
	15	TIBBETTS, et al., "Linear and cyclic LFA-1 and ICAM-1 peptides inhibit T cell adhesion and function", Peptides, vol. 21, pgs. 1161-1167, (2000). <input type="checkbox"/>
	16	VALADON, et al., "Enhancement of ELISAs for screening peptides in epitope phage display libraries", Journal of Immunological Methods, vol. 197, pgs. 171-179, (1996). <input type="checkbox"/>
	17	VON MUTIUS, et al., "International patterns of tuberculosis and the prevalence of symptoms of asthma, rhinitis, and eczema", Thorax, vol. 55, pgs. 449-453, (2000). <input type="checkbox"/>
	18	VYAS, et al., "Structural basis of peptide-carbohydrate mimicry in an antibody-combining site", PNAS, vol. 100, no. 25, pgs. 15023-15028, (2003). <input type="checkbox"/>
	19	WANG, et al., "Epitope Identification and Discovery Using Phage Display Libraries: Applications in Vaccine Development and Diagnostics", Current Drug Targets, vol. 5, pgs. 1-15, (2004). <input type="checkbox"/>
	20	WU, et al., "The Pharmacological Actions of Nicotine on the Gastrointestinal Tract", Journal of Pharmacological Sciences, vol. 94, pgs. 348-358, (2004). <input type="checkbox"/>
	21	YOSHIMURA, et al., "Role of NF $\kappa$ B in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI", Eur. J. Immunol., vol. 31, pgs. 1883-1893, (2001). <input type="checkbox"/>
	22	ZABROCKI, et al., "Conformational Mimicry. 1. 1,5-Disubstituted Tetrazole Ring as a Surrogate for the Cis Amide Bond", J. Am. Chem. Soc., vol. 110, pgs. 5875-5880, (1988). <input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number		10589866
	Filing Date		2006-09-19
	First Named Inventor		BERCOVIER
	Art Unit		1645
	Examiner Name		DEVI
	Attorney Docket Number		27637U

23	ZECHEL, et al., "Synthetic glucagon antagonists and partial agonists", Int. J. Peptide Protein Res., vol. 38, pgs. 131-138, (1991).	<input type="checkbox"/>
24	ZUANY-AMORIM, et al., "Suppression of airway eosinophilia by killed mycobacterium vaccae-induced allergen-specific regulatory T-cells", Nature Medicine, vol. 8, no. 6, pgs. 625-629, (2002).	<input type="checkbox"/>
25	MIYAKK, et al., "1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid Angiotensin: Synthesis and Angiotensin Converting Enzyme Inhibitory Activity of 1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid Derivatives", J. Takeda Res. Labs., vol. 43, pgs. 53-76, (1984).	<input type="checkbox"/>
26	DELUCA, et al., "Parenteral Drug-Delivery Systems", Pharmaceutics and Pharmacy Practice, ch. 8, pgs. 238-250, J.B. Lippincott Co., Philadelphia, Pa., Bunker and Chalmers, eds., (1982).	<input type="checkbox"/>
27	TRISSEL, "Intravenous Infusion Solutions", ASHP Handbook on Injectable Drugs, 4th ed., pgs. 622-630, (1986).	<input type="checkbox"/>
28	ENSHELL-SEIJFFERS, et al., "Phage Display Selection and Analysis of Ab-Binding Epitopes", Current Protocols in Immunology, vol. 2, pgs. 9.8.1-9.8.27, (2002).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

#### EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.